| Peter W Dienhart, MD | |
|
410 W 10th Ave, Columbus, OH 43210-1240 | |
| (614) 293-8487 | |
| (614) 293-8153 |
| Full Name | Peter W Dienhart |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 24 Years |
| Location | 410 W 10th Ave, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164649588 | NPI | - | NPPES |
| 2804504 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 35-089511 (Ohio) | Secondary |
| 207L00000X | Anesthesiology | 35-089511 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohio State University State Health System | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Osu Observation Medicine, Llc | 3375692270 | 370 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.
Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.
Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.
A study of thousands of patients' health records found that those who were prescribed cholesterol-lowering statins had at least double the risk of developing type 2 diabetes.
› Verified 1 days ago
| Entity Name | Osu Health System Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174581185 PECOS PAC ID: 8426959214 Enrollment ID: O20040115000490 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.
Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.
Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.
A study of thousands of patients' health records found that those who were prescribed cholesterol-lowering statins had at least double the risk of developing type 2 diabetes.
› Verified 1 days ago
| Entity Name | Osu Observation Medicine, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407095052 PECOS PAC ID: 3375692270 Enrollment ID: O20090526000354 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.
Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.
Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.
A study of thousands of patients' health records found that those who were prescribed cholesterol-lowering statins had at least double the risk of developing type 2 diabetes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter W Dienhart, MD 700 Ackerman Rd Ste 570, Columbus, OH 43202-1579 Ph: (614) 293-8487 | Peter W Dienhart, MD 410 W 10th Ave, Columbus, OH 43210-1240 Ph: (614) 293-8487 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.
Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.
Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.
A study of thousands of patients' health records found that those who were prescribed cholesterol-lowering statins had at least double the risk of developing type 2 diabetes.
› Verified 1 days ago
Dr. Matthew Lane Garvey, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5151 Reed Rd, Suite 225-c, Columbus, OH 43220 Phone: 614-457-2306 Fax: 614-884-0776 | |
Rafal Kopanczyk, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-8487 Fax: 614-293-8153 | |
Senthil Gopala Krishna, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 700 Childrens Drive, Section Of Anesthesiology, Columbus, OH 43205 Phone: 614-722-4200 Fax: 614-722-4203 | |
Manoj H. Iyer, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-8487 Fax: 614-293-8153 | |
Alvaro R Camacho Ortega, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-8487 Fax: 614-293-8153 | |
Douglas E Yunker, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5151 Reed Rd, Suite 225-c, Columbus, OH 43220 Phone: 614-457-2306 Fax: 614-884-0776 | |
Nadia Salama Nathan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 410 West Tenth Ave, N429 Doan Hall, Columbus, OH 43210 Phone: 614-293-4705 Fax: 614-293-8153 |